Patents Issued in September 17, 2024
  • Patent number: 12090200
    Abstract: The present invention relates generally to immunotherapy for preventing HIV infection in HIV-negative individuals. In particular, the methods include methods for making cells resistant to HIV and administering an immune therapy to an HIV-negative subject to prevent an HIV infection.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: September 17, 2024
    Assignee: American Gene Technologies International Inc.
    Inventors: Charles David Pauza, Haishan Li, Tyler Lahusen
  • Patent number: 12090201
    Abstract: Methods for treating moderate-to-severe or severe atopic dermatitis in a pediatric subject are provided. In one aspect, the methods comprise administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.
    Type: Grant
    Filed: August 5, 2020
    Date of Patent: September 17, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ashish Bansal, Neil Graham, Paola Mina-Osorio, John Davis, Mohamed Kamal
  • Patent number: 12090202
    Abstract: A method of use of plasma immunoglobulin, such as intramuscular immunoglobulin, in combination with polyclonal antigen-specific immunoglobulin in the treatment or prevention of allergic disease is provided. Also provided is a pharmaceutical composition including plasma immunoglobulin in combination with polyclonal antigen-specific immunoglobulin.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: September 17, 2024
    Assignee: NETWORK IMMUNOLOGY INC.
    Inventors: Geoffrey William Hoffmann, Reginald M. Gorczynski
  • Patent number: 12090203
    Abstract: The present invention provides methods for preparing acoustically-sensitive microbubbles. The method includes the steps of: i) preparing a first surfactant solution comprising a first micelle-forming surfactant at a concentration above the critical micelle concentration (CMC); ii) adding one or more pharmaceutical compounds in a solvent to the first surfactant solution, thereby loading the micelles with the one or more pharmaceutical compounds; iii) preparing a second surfactant solution comprising a second surfactant, wherein the second surfactant comprises one or more matrix forming surfactants; iv) adding heat to the second surfactant solution to melt the surfactant and allowing the mixture to cool under rapid stirring; v) combining the second surfactant solution with the loaded micelles; vi) purging the surfactant mixture with a purging gas; vii) agitating the purged mixture under a constant stream of the purging gas; and, viii) separating the formed microbubbles by size.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: September 17, 2024
    Assignees: Drexel University, Thomas Jefferson University
    Inventors: Margaret A. Wheatley, John Robert Eisenbrey, Brian E. Oeffinger, Purva Vaidya
  • Patent number: 12090204
    Abstract: A composition and method directed to the treatment of bacterial infections is provided.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: September 17, 2024
    Assignee: Pinnacle Biologics, Inc.
    Inventors: Glenn M. Kutschera, Thomas S. Mang
  • Patent number: 12090205
    Abstract: The reduction in the sol-gel temperature of aqueous poloxamer surfactant compositions by the addition of hydrophobic vicinal diols is provided. Lowering of the sol-gel temperature and the gelling efficiency of water-soluble poloxamer block copolymers of polyethylene oxide-b-polypropylene oxide-b-polyethylene oxide has been markedly improved by the addition of small amounts of at least one hydrophobic vicinal diol, such as monoalkyl glycols, monoalkyl glycerols, or monoacyl glycerols. The decrease in the sol-gel temperature facilitates gel formation, and such gels exhibit greater residence time on a surface, particularly those with biological properties.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: September 17, 2024
    Assignee: ROCHAL TECHNOLOGIES LLC
    Inventors: Joseph C. Salamone, Rebecca Erin McMahon, Suprena Emanuella Zariah Poleon, Ann Beal Salamone
  • Patent number: 12090206
    Abstract: Disclosed herein are mixtures of triblock or pentablock copolypeptide hydrogels (DCH). These hydrogels possess improved mechanical properties, such as elasticity, that are synergistically increased over the individual component DCHs, to greater than would be expected for a linear combination of the components. Also disclosed herein are methods of making and using the triblock and pentablock copolypeptide hydrogels.
    Type: Grant
    Filed: April 23, 2021
    Date of Patent: September 17, 2024
    Assignee: The Regents of the University of California
    Inventors: Timothy J. Deming, Yintao Sun
  • Patent number: 12090207
    Abstract: The disclosure provides a drug delivery composition, method of forming the same and method for treating inner ear disorders. The drug delivery composition includes a temperature sensitive hydrogel, a plurality of microbubbles and a drug. Every microbubble has a protein shell and an inert gas core. These microbubbles are dispersed in the temperature sensitive hydrogel. The drug is dispersed in the temperature sensitive hydrogel. Moreover, the drug delivery composition has a viscosity that can induce cavitation effect.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: September 17, 2024
    Assignees: National Taiwan University of Science and Technology, National Defense Medical Center
    Inventors: Ai-Ho Liao, Chih-Hung Wang, Cheng-Ping Shih
  • Patent number: 12090208
    Abstract: The invention involves the coupling of compounds that can be bound by Haptocorrin (R-binder; Transcobalamin I; HC) to a target drug to improve pharmacokinetics, avoid undesirable side effects, and/or modify CNS access and localization. The pharmaceutical effect may be improved by conjugating the drug to haptocorrin binding substrate. This allows the conjugate to become bound to unsaturated haptocorrin in the blood, thereby protecting the drug from metabolism or excretion to increase protein half-life while not interfering with the efficacy of the protein drug. The conjugation may additionally prevent the drug from reaching the central nervous system or modify where the drug localizes and produces undesirable side effects such as nausea or hypophagia. Such a route also would prevent, in all case save for actual vitamin B12, binding by serum transcobalamin II (TCII), and thus not cause B12 deficiency with long term use.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: September 17, 2024
    Assignee: SYRACUSE UNIVERSITY
    Inventor: Robert Doyle
  • Patent number: 12090209
    Abstract: Functionalized twin base linkers (TBLs) bind to and deactivate viruses by preventing their entry into cells. Functionalization of TBLs allows them to specifically bind to surface proteins of viruses, where they form structures that limit virus entry into cells and prevent viruses from replicating.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: September 17, 2024
    Assignees: Northeastern University, Audax Medical, Inc.
    Inventors: Thomas J. Webster, Mark A. Johanson
  • Patent number: 12090210
    Abstract: The present disclosure relates to an antibody-drug conjugate in which a modified antibody comprising a motif having a specific structure at the end of the antibody is conjugated to a drug via a linker, and a composition comprising the same, and more particularly to a modified antibody-drug conjugate (mADC) comprising a modified antibody that has a significantly increased conjugation yield of drug due to a motif bound to the heavy chain or light chain C-terminus of the antibody, and to a composition comprising the same.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: September 17, 2024
    Assignee: ALTEOGEN, INC.
    Inventors: Soon Jae Park, Hye-Shin Chung, Sunbae Lee, Minsoo Byun
  • Patent number: 12090211
    Abstract: The subject matter described herein is directed to methods of preparing certain antibody-drug conjugates (ADCs) wherein the antibody is linked to the drug through a linker, wherein the drug contains a heteroaryl group having a secondary nitrogen, and the linker is attached to the drug via the secondary nitrogen. The resulting conjugates are useful in treating various diseases and conditions.
    Type: Grant
    Filed: November 21, 2022
    Date of Patent: September 17, 2024
    Assignee: Genentech, Inc.
    Inventors: Thomas Pillow, Peter Dragovich
  • Patent number: 12090212
    Abstract: Antibody drug conjugates (ADC's) comprising a drug conjugated to antibody or antigen binding fragments thereof that bind to Globo series antigen disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: September 17, 2024
    Assignee: OBI Pharma, Inc.
    Inventors: Michael Nientse Chang, Jiann-Shiun Lai, Wan-Fen Li, I-Ju Chen, Yi-Chien Tsai, Kai-Chuan Chen
  • Patent number: 12090213
    Abstract: Exosomes that express peptides in CD9 proteins, and smart exosomes that co-express two peptides incorporated into CD9 proteins to home delivery of the exosomes to a desired target and evade phagocytosis by macrophages, are described. Provided are exosomes useful for delivering drugs to desired targets. The exosomes comprise drugs, such as chemotherapeutic drugs, encapsulated in their core. The targets include pancreatic cancer cells.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: September 17, 2024
    Assignee: The University of Toledo
    Inventors: Shi-He Liu, Francis Charles Brunicardi
  • Patent number: 12090215
    Abstract: The present disclosure is generally related to methods, systems and devices for direct production of a radioisotope-based cancer treatment pharmaceutical directly from a corresponding non-radioactive drug molecule precursor by irradiating the non-radioactive drug molecule precursor using neutrons produced by an electronic neutron generator array or other neutron generator sources.
    Type: Grant
    Filed: February 4, 2022
    Date of Patent: September 17, 2024
    Assignee: Westinghouse Electric Company LLC
    Inventors: Michael D. Heibel, James Boyle, Kris Paserba
  • Patent number: 12090216
    Abstract: Disclosed are compositions, such as makeup removing compositions, that can form a film on a keratin material, such as skin that lifts and removes makeup from the keratin material, such as skin. The compositions may be an aqueous composition including: (a) a hydrophobically modified acrylate film forming homopolymer or copolymer; (b) a hydrophilic film forming polymer; (c) a volatile oil; (d) a nonionic surfactant; (e) optionally, a monoalcohol having from 2 to 5 carbon atoms; and (f) water. Alternatively, the compositions may be anhydrous compositions including: (a) a hydrophobically modified acrylate film forming homopolymer or copolymer; (b) a plasticizer; and (c) a volatile oil. Also disclosed are methods for cleansing and removing makeup from keratin material, such as skin.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: September 17, 2024
    Assignee: L'OREAL
    Inventors: Tianyi Liu, Koji Endo, Prabhjot K. Saini
  • Patent number: 12090217
    Abstract: A method of treating keratinous substrates, includes applying a makeup setting composition to a keratinous substrate having makeup formed thereon. The makeup setting composition includes a gas phase dispersed in a condensed phase. The condensed phase includes a water-soluble or water-dispersible film former. Kits and mousse-forming compositions are also provided.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: September 17, 2024
    Assignee: L'OREAL
    Inventors: Roselin Rosario-Melendez, Stan Najmr, Anne-Laure Bernard
  • Patent number: 12090218
    Abstract: To provide a water-in-oil emulsified composition which highly encapsulates a water content, has high viscosity, and is excellent in emulsification stability. The water-in-oil emulsified composition of the present disclosure comprises a dispersion medium comprising an oil content, and an oil-soluble copolymer having a monomer unit obtained from a specific hydrophilic monomer, and a monomer unit obtained from a specific hydrophobic monomer; and water droplets dispersed in the dispersion medium, wherein the oil content contains 60% by mass or more of polar oil with an IOB of 0.10 or more, and wherein the water droplets contain water and a surfactant, and the content of the water is 30% by mass or more based on the total amount of the composition.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: September 17, 2024
    Assignee: Shiseido Company, Ltd.
    Inventors: Makoto Uyama, Takumi Watanabe, Ayano Matsuo
  • Patent number: 12090219
    Abstract: Disclosed is a method of exfoliating a person's skin. The method can include obtaining an apparatus that includes: (a) a water-permeable absorbent material, wherein the water-permeable absorbent material is a sponge, cloth, or mesh which has a first outer surface and a second outer surface; and (b) a composition comprising a plant material, a plant extract, or a combination thereof, wherein the plant material, the plant extract, or the combination thereof comprises salicylic acid, Matricaria recutita extract, and Aloe vera extract. The method can also include contacting the apparatus with water for a sufficient period of time so as to release, solubilize, or release and solubilize the plant material, the plant extract, or the combination thereof to yield a treated apparatus and contacting and cleansing the facial skin with the treated apparatus.
    Type: Grant
    Filed: August 10, 2023
    Date of Patent: September 17, 2024
    Assignee: MARY KAY INC.
    Inventors: Daniel Chen, James Swanzy
  • Patent number: 12090220
    Abstract: The present invention relates to sunscreen or daily care compositions comprising hexyl 2-[4-(diethylamino)-2-hydroxybenzoyl]benzoate (INCI diethylamino hydroxybenzoyl hexyl benzoate), 1-(4-(1,1-dimethylethyl)phenyl)-3-(4-methoxyphenyl)propane-1,3-dione (INCI butyl methoxydibenzoylmethane) and at least one organic particulate UV filter, wherein the composition does not comprise 2-hydroxy-4-methoxybenzophenone (INCI oxybenzone) and ethylhexyl-2-cyano-3,3-diphenyl-acrylate (INCI octocrylene).
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: September 17, 2024
    Assignee: BASF SE
    Inventors: Myriam Sohn, Stanislaw Krus, Marcel Schnyder, Stephanie Acker
  • Patent number: 12090221
    Abstract: The present disclosure relates to a composition for preventing gray hair, promoting black hair and preventing, improving or treating vitiligo or hypochromatism, which contains fructose 1,6-bisphosphate or a salt, a solvate, a stereoisomer or a hydrate thereof as an active ingredient, and has been contrived to solve the problem of the prior art that appreciable effect cannot be achieved due to insignificant effect on melanin production. The composition of the present disclosure, which contains fructose 1,6-bisphosphate or a salt, a solvate, a stereoisomer or a hydrate thereof, provides superior effect of preventing gray hair, promoting black hair and treating vitiligo or hypochromatism.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: September 17, 2024
    Assignee: AMOREPACIFIC CORPORATION
    Inventors: Hyunjung Choi, Seunghyun Shin, Hyoung June Kim, Wonseok Park
  • Patent number: 12090222
    Abstract: The subject of the present disclosure is a method for dyeing keratinous material, in particular human hair. The method includes applying an agent (a) to the keratinous material. The agent (a) includes one or more organic silicon compound selected from the group of silanes having one, two or three silicon atoms, (a2) a first colorant compound including one or more lenticular substrate platelet-based pigment, and (a3) a second coloring compound. The method further includes applying an agent (b) to the keratinous material. The agent (b) includes at least one sealing reagent. Also disclosed are multi-component packaging unit (kit-of-parts) for dyeing keratinous material.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: September 17, 2024
    Assignee: HENKEL AG & CO. KGAA
    Inventors: Gabriele Weser, Torsten Lechner, Juergen Schoepgens, Carsten Mathiaszyk, Marc Nowottny, Ulrike Schumacher, Caroline Kriener, Claudia Kolonko, Phillip Jaiser
  • Patent number: 12090223
    Abstract: A method of manufacturing a cosmetic composition by preparing a mixture that includes a sucrose esters and one or more solvents. The sucrose ester can have a fatty acid portion having from about 12 to about 24 carbon atoms and the sucrose esters can be selected from the group consisting of mono-ester, di-ester, tri-ester, tetra-ester, and mixtures thereof. The one or more solvents can have Hildebrand Solubility Parameter of from about 23 to about 31.5(J/cm3)1/2 and Polar component of Hansen Solubility Parameter of from about 4.5 to about 10.5 (J/cm3)1/2. The sucrose ester can be dissolved in the cosmetic compositions, even when the sucrose ester is contained at higher levels in the compositions and/or even when the sucrose esters are contained in an aqueous phase of the cosmetic composition.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: September 17, 2024
    Assignee: The Procter & Gamble Company
    Inventors: Shuhei Tanaka, Akiko Tada
  • Patent number: 12090224
    Abstract: The present disclosure relates to stable cosmetic compositions containing high amounts of ceramide NP. The cosmetic compositions further include high amounts of hydroxypropyl tetrahydropyrantriol, a plurality of emulsifiers, fatty alcohols, fatty compounds, and water. Methods for stabilizing the cosmetic compositions containing high amounts of ceramide NP and methods for treating the skin with the cosmetic compositions is also described.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: September 17, 2024
    Assignee: L'OREAL
    Inventors: Jonathan James Faig, Susan Halpern Chirch, Angelike Galdi, Yon Jae Yoon, David Chan
  • Patent number: 12090225
    Abstract: Disclosed herein are formulations of nintedanib and salts thereof, indolinone derivative compounds and salts thereof for aerosolization and use of such formulations for the prevention or treatment of various fibrotic, carcinogenic, vascular and viral infectious diseases, including diseases associated with the lung, heart, kidney, liver, eye, central nervous system and surgical sites. Formulations and delivery options described herein allow for efficacious local delivery of nintedanib or a indolinone derivative compound or salt thereof. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described. Also included are methods for identifying compounds and indications that benefit by reformulation and inhalation administration.
    Type: Grant
    Filed: September 8, 2021
    Date of Patent: September 17, 2024
    Assignee: Avalyn Pharma Inc.
    Inventors: Mark William Surber, Stephen Pham
  • Patent number: 12090226
    Abstract: The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
    Type: Grant
    Filed: February 27, 2024
    Date of Patent: September 17, 2024
    Assignee: Cristcot LLC
    Inventors: Jennifer J. Davagian, Raj Devarajan
  • Patent number: 12090227
    Abstract: The present disclosure relates to a method to improve the encapsulation efficiency and physicochemical stability of ginsenosides Rg3 and CK nano-emulsion, belonging to the field of functional emulsions. The method to improve the encapsulation efficiency and physicochemical stability of ginsenosides Rg3 and CK nano-emulsion, includes the following steps: (1) WPI, Tween 80 and water were mixed evenly according to the amount ratio of 0.5 g:0.5-0.7 g:50 mL to obtain the aqueous phase; (2) Mixing a saponin extract containing the minor ginsenosides Rg3 and CK with edible oil evenly to obtain the oil phase; (3) Mixing the aqueous phase with the oil phase, carrying out shearing dispersion to obtain coarse emulsion, and then allowing the coarse emulsion to be subjected to microfluidization homogenization to obtain an oil-in-water nano-emulsion containing the minor ginsenosides Rg3 and CK.
    Type: Grant
    Filed: December 1, 2023
    Date of Patent: September 17, 2024
    Assignees: JIANGNAN UNIVERSITY, STANDARD FOODS (CHINA) CO., LTD, LE BONTA WELLNESS CO., LTD
    Inventors: Peng Zhou, Changshu Liu, Yaowei Liu, Tao Yang, Yan Zheng, Jianguo Liu, Kexin Li, Shuyan Lu
  • Patent number: 12090228
    Abstract: There is provided a package wherein a pharmaceutical composition containing a saccharide-degrading enzyme is contained in a container, whereby reduction in titer caused by a low amount of enzyme is suppressed. A package comprising a pharmaceutical composition and a container, wherein the pharmaceutical composition is a lyophilized preparation containing a saccharide-degrading enzyme as an active ingredient, and the container contains the pharmaceutical composition, the inner surface of the container comprising at least one material selected from the group consisting of fine ceramics, silicone resins and fluorine resins.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: September 17, 2024
    Assignee: SEIKAGAKU CORPORATION
    Inventor: Mine Higuchi
  • Patent number: 12090229
    Abstract: Disclosed herein are compositions and methods for cellular reconstitution of photopolymerized, lyophilized, bioactive chondroitin sulfate glycosaminoglycan (CS-GAG)-based hydrogel matrices.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: September 17, 2024
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Lohitash Karumbaiah, Leidong Mao, Meghan T. Logun, Wujun Zhao
  • Patent number: 12090230
    Abstract: The present invention is a cannabidiol oral dosage form including predominantly or exclusively bacterially fermented hemp pomace, compounded as a tablet or formulated within a capsule generally without the addition of synthetic excipients, fillers or other additives, not including the inevitable presence of some moisture. The dosage forms contain dietary fiber, important to activity as the desired delivery system, having a ratio of one part soluble dietary fiber to 30 parts insoluble dietary fiber and delivers desirable/non hallucinogenic cannabinoids (CBD, CBG, etc.) in a ratio of 60:1 up to 120:1 to hallucinogenic cannabinoids (THC).
    Type: Grant
    Filed: November 2, 2022
    Date of Patent: September 17, 2024
    Assignee: Fermented Farmer, LLC
    Inventor: Jordan Seth Rubin
  • Patent number: 12090231
    Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
    Type: Grant
    Filed: October 17, 2022
    Date of Patent: September 17, 2024
    Assignee: LABORATORIOS LEON FARMA SA
    Inventors: Philippe Perrin, Jose Luis Velada, Dominique Drouin
  • Patent number: 12090232
    Abstract: Enteric softgel capsules comprise a fill material and an enteric shell composition, characterized in that the enteric nature of the capsules may be achieved without an enteric coating or added conventional enteric polymers.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: September 17, 2024
    Assignee: R.P. Scherer Technologies, LLC
    Inventors: Humera Ahmad, Jonathan Do, Jing Lin
  • Patent number: 12090233
    Abstract: Masking particles which comprise a drug-containing particle containing a drug, an acid, and a carbonate, the drug-containing particle being coated with a coating layer containing a water-insoluble polymer sufficiently suppress drug release in the oral cavity and pharynx, rapidly release a drug after swallowing, and easily control the release suppression time of a drug. The acid may be at least one organic acid. The carbonate may be at least one water-soluble carbonate. Oral pharmaceutical compositions include tablets, granules, fine granules, powders.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: September 17, 2024
    Assignee: TOWA PHARMACEUTICAL CO., LTD.
    Inventors: Tatsuya Honjo, Megumi Murahashi, Masaki Sato, Kayo Yuminoki, Isamu Saeki, Yutaka Okuda
  • Patent number: 12090234
    Abstract: Disclosed herein are compositions and methods related to megakaryocyte-derived extracellular vesicles derived from human pluripotent stem cells, where the megakaryocyte-derived extracellular vesicles may be utilized for drug delivery and treating various diseases.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: September 17, 2024
    Assignee: STRM.bio Incorporated
    Inventor: Jonathan Thon
  • Patent number: 12090235
    Abstract: The present disclosure provides methods of producing lipid nanoparticle (LNP) formulations and the produced LNP formulations thereof. The present disclosure also provides therapeutic and diagnostic uses related to the produced LNP formulations.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: September 17, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Allen Horhota, Christopher Karl McLaughlin, Jessica Cheney, Ben Geldhof, Jeffrey Hrkach, Melissa J. Moore, Stephen G. Hoge
  • Patent number: 12090236
    Abstract: Efficient and adequate disposal of medical infectious waste is proportional to the reduction of the spread of infectious diseases and the disease itself among humans. The essence of this invention is that infectious medical waste is in a timely, fast, efficient, simple, and environmentally friendly safely disposed of and turned into inert-municipal waste. Previous methods and devices for the disposal of infectious medical waste involved long-term procedures for the collection, sorting and storage of infectious medical waste, which increases the risk of secondary infections. This invention skips the process of collecting, sorting and storing medical infectious waste, and the entire process in the invention takes place in three unbreakable phases whose end product is municipal-inert waste. It is important to emphasize that with this invention, even the smallest amount of infectious medical waste will be disposed of immediately in an appropriate manner.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: September 17, 2024
    Inventor: Katarína Ponjavić
  • Patent number: 12090237
    Abstract: A metal ionic antimicrobial surface configured for external use on a surface location in an indoor environment. A surface structure includes a pair of opposed major surfaces, one surface forming an exposed layer having a pattern of conductive strips and corresponding insulative spacings with a power pod structure secured to the surface structure. The power pod structure houses a battery and a power control circuit electrically connected to the conductive strips. In embodiments, the battery has an amp-hour capacity of 150-1500 mAh, an average width of each conductive strip of copper and silver metallic ions and each insulative spacing is between 0.1 to 0.5 millimeters, and the power control circuit includes a voltage booster circuit that maintains a constant low voltage of 2.5V-4.5V.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: September 17, 2024
    Inventors: Christopher M. Wharton, Zackary G. Lowe, Charles G. Rudolf, Thomas A. Fuller, David K. Tabbutt, Mark D. Loewen, Seth R. Zimmerman
  • Patent number: 12090238
    Abstract: A compact, portable, low cost ultraviolet (UV) light source apparatus irradiates select or target surfacing for disinfecting or sanitizing the target surfacing or for decomposing ozone within a defined ozone environment. The ultraviolet light source apparatus according to the present invention essentially includes a power source; an ultraviolet (UV) light source in communication with the power source, and a mechanism for powering on and powering off the ultraviolet (UV) light source. The ultraviolet (UV) light source directs ultraviolet light toward a select surface for irradiating the surface or decomposing ozone. The ultraviolet (UV) light source apparatus may be attached to any number of select surfaces or objects or may be utilized to receive and hold objects for treating surfacing thereof.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: September 17, 2024
    Inventor: Andrew B. Rifkin
  • Patent number: 12090239
    Abstract: A disinfection chamber for disinfecting objects placed within an interior space of the disinfection chamber. The chamber includes a plurality of LED fixtures and one or more shelves. The LED fixtures each comprise LED ultraviolet sources and at least one LED visible light source. The ultraviolet sources are configured to emit germicidal ultraviolet light. Each of the shelves comprise a grill frame configured to support and position objects. A first shelf of the one or more shelves is positioned at or near a floor of the interior space. A first LED fixture is positioned upon the first shelf and beneath the grill frame. A second LED fixture is positioned at or near a ceiling of the interior space. The first and second LED fixtures are arranged within the interior space, such that objects placed within the interior space will be disinfected by the ultraviolet sources.
    Type: Grant
    Filed: March 24, 2022
    Date of Patent: September 17, 2024
    Assignee: Blu Perspective LLC
    Inventors: Corbin Collet, April Jennesis-Collet, Brian Brandon
  • Patent number: 12090240
    Abstract: An apparatus for reducing pathogen loading is disclosed. A plasma processing chamber is sealed at one end and a pressure sealable door at the other end, with electrodes within the chamber. A first electrode is coupled to a RF power source and a second electrode is coupled to ground. An inlet port introduces a process gas into the chamber. A vacuum pump draws the process gas into the chamber and exhausts through the pump. An object is positioned within an inside wall of the chamber. A surface of the object is disinfected when a plasma field is generated when RF energy from the electrodes is applied to the introduced process gas.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: September 17, 2024
    Assignee: MagPlasma, Inc.
    Inventors: Martin E. Toomajian, Kevin D. Hawley
  • Patent number: 12090241
    Abstract: The present invention is generally related to an apparatus and method for sanitizing a continuous positive airway pressure (CPAP) device, in particular the invention relates to a system, method and device that attach to a CPAP device and sanitizes all of the parts of the CPAP device, including the inner areas of the hose, reservoir and face mask most prone for bacteria buildup. The device has an ozone operating system and one or more ozone distribution lines that distributes ozone to a CPAP device and a non-permeable bag for sanitizing a CPAP mask.
    Type: Grant
    Filed: March 20, 2023
    Date of Patent: September 17, 2024
    Assignee: SOCLEAN INC.
    Inventors: Michael U. Schmidt, Timothy Leyva, Mariusz Surowaniec
  • Patent number: 12090242
    Abstract: A hydrogen peroxide sterilization device for sterilizing a medical device, the hydrogen peroxide sterilization device including a hermetic outer container, a hydrogen peroxide pouch, and a hydrogen peroxide solution in the solution chamber. The hermetic outer container includes a sterilization enclosure configured to receive the medical device. The hydrogen peroxide pouch includes a permeable membrane enclosing a solution chamber and is configured to be positioned in the sterilization enclosure of the outer container. The permeable membrane is configured to allow hydrogen peroxide vapor to diffuse from the solution chamber through the permeable membrane into the sterilization enclosure.
    Type: Grant
    Filed: April 28, 2023
    Date of Patent: September 17, 2024
    Assignee: Honeywell Federal Manufacturing & Technologies, LLC
    Inventors: George William Bohnert, Darren Radke, Domenick Leto
  • Patent number: 12090243
    Abstract: The present disclosure is directed to an injectable composition in form of fluid gel and the use thereof to assist the tissues resection during endoscopic procedures in which it is injected in the tissue of interest to form a cushion for tissue separation. Aspects of the composition can include a gelling agent, a modifier, a salt and water. The composition can be prepared by mixing the gelling agent, modifier, at least one salt and water via continuous stirring to obtain fluid gel solutions, wherein modifier enables the said fluid gel composition to be injected into the submucosal layer of gastrointestinal tissues through endoscopic injection catheter and needle with significantly reduced injection pressure and generate a high and durable cushion for long-lasting tissue raise-up in the submucosal layer, for the application of injection assisted resection procedures.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: September 17, 2024
    Assignee: ALEO BME, INC.
    Inventors: Chao Liu, Chuying Ma, Xuedi Yu
  • Patent number: 12090244
    Abstract: Compositions and methods for sealing tissue of a patient in a wet environment are disclosed.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: September 17, 2024
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Yves A. Delmotte, Jonathan Payssan
  • Patent number: 12090245
    Abstract: A tissue adhesive membrane and a preparation method thereof are provided. The tissue adhesive membrane includes a supramolecular polymer and an enhancer; the supramolecular polymer is prepared by copolymerization of lipoic acid and a biocompatible stabilizer; and the enhancer includes at least one selected from the group consisting of a cationic compound, a cationic polymer, and a metal particle. The tissue adhesive membrane of the present invention can achieve rapid adhesion, seal wounds continuously and effectively, and maintain long-lasting mechanical strength. The components of the tissue adhesive membrane come from natural components of animals and plants, have good biocompatibility, and possess the functions of antibacterial and inhibiting inflammation. The tissue adhesive membrane of the present invention is a hydrophobic adhesive membrane where hydrogen bonding and high surface energy can provide strong adhesion energy and no adverse active groups that may cause irritation or discomfort are contained.
    Type: Grant
    Filed: May 9, 2023
    Date of Patent: September 17, 2024
    Assignee: SOUTH CHINA UNIVERSITY OF TECHNOLOGY
    Inventors: Xuetao Shi, Wei Yang
  • Patent number: 12090246
    Abstract: The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: September 17, 2024
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Ali Khademhosseini, Nasim Annabi, Alexander Assmann
  • Patent number: 12090247
    Abstract: A water-soluble sealant composition and a method for preparing the same which includes: adding soluble silver salt to a polyacrylic acid (PAA) solution; adjusting the pH of the PAA solution to 7-7.4; and heating the PAA solution to 90-125° C. The PAA has a molecular weight between 1000 to 8000. The composition includes a cross-linked poly(acrylic) silver matrix having affinity to proteins. The silver salt can be silver nitrate and/or silver acetate. The matrix may create hydrophilic zones which bind proteins. The composition when in contact with proteins may form hexagonal packing complexes of rod-like poly(acrylic) particles and proteins. It may form a clot made of multi-layered grid structure. In some cases, the complexes create loops that form cells comprising proteins e.g., albumin. The proteins may be of a body fluid such as blood, lymph and combinations thereof. The composition may be applied for a medical condition such as hemorrhage and lymphorrhea.
    Type: Grant
    Filed: January 25, 2021
    Date of Patent: September 17, 2024
    Inventors: Alexander Plotkin, Dmitri Menglet
  • Patent number: 12090248
    Abstract: Provided are a crosslinked hyaluronic acid product in the form of powder and a method of preparing the same, and a crosslinked hyaluronic acid hydrogel prepared using the crosslinked hyaluronic acid product in the form of powder, and a method of preparing the same. The crosslinked hyaluronic acid hydrogel according to the present disclosure exhibits excellent rheological properties, and mass production thereof is easy and quality uniformity thereof is excellent.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: September 17, 2024
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Soo Jin Kim, Se Kweon Kim, Chung Leol Shin, Hyo Seung Park, Yong Woo Kim, Back Ho Lee, Jun Young Kim
  • Patent number: 12090249
    Abstract: An implant is provided comprising a substrate having one or more nanoceria coatings coated at least partially thereon, wherein the one or more nanoceria coatings comprise surface cerium having a 3+/4+ oxidation state ratio such that the one or more nanoceria coatings exhibit catalase mimetic activity, superoxide dismutase mimetic activity, or both. Methods are provided for forming a nanoceria coating. The coating has nanoceria having a surface cerium 3+/4+ oxidation state ratio such that such that the coating exhibits catalase mimetic activity, superoxide dismutase mimetic activity, or both. Also disclosed is a method of reducing degradation of an implant by placing nanoceria in proximity to a bone-implant interface.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: September 17, 2024
    Assignees: University of Central Florida Research Foundation, Inc., Sanford Burnham Prebys Medical Discovery Institute
    Inventors: Sudipta Seal, Soumen Das, William Self, Dwight Towler
  • Patent number: 12090250
    Abstract: The present invention provides demineralized bone fibers exhibiting optimal handling properties (e.g., high moldability and low elastic modulus) and biological activities (e.g., osteoinductivity) as well as non-demineralized bone fibers useful for preparing the demineralized bone fibers. A well-controlled demineralization process for preparing the demineralized bone of fibers is also provided. Products comprising the demineralized bone fibers and uses thereof are further provided.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: September 17, 2024
    Assignee: LifeNet Health
    Inventors: Silvia Chen, Grant Cleavenger, Dennis Phelps, Evans Wralstad, Breanne Gjurich, Austin Johnson, Alana Sampson, Adam Entsminger, Jingsong Chen